Dyne Therapeutics - Bathi operasional EBITDA DYN

The resilience of Dyne Therapeutics, Inc. (DYN) is based on access to global investments and patent protection. The EBITDA trend on the GURU.Markets chart confirms this stability, where 0.00 captures the current state of the parameter. Revenue growth relies on the development of muscular dystrophy therapies, while financial reliability is supported by liquidity and the control of costs associated with oligonucleotide clinical trials.

DYN - Bathi sadurunge mbayar bunga, pajak, lan amortisasi Dyne Therapeutics ing rentang 23.11.2025 - 12.11.2026

Ringkesan rincian data analitis Dyne Therapeutics (DYN)

- nilai pasar lan prakiraan target analis:

Rega bursa Dyne Corp|DYN - Target konsensus

- rincian nilai pasar emiten:

Kapitalisasi pasar Dyne Therapeutics|DYN - Nilai Total Perusahaan

- indikator nilai buku ekuitas:

Nilai Akuntansi Saham Dyne Therapeutics|DYN - Nilai Buku Perusahaan|Koefisien Nilai Pasar marang Nilai Buku dyne-tx.com|DYN - Aset Agregat Perusahaan

- data tingkat utang lan likuiditas finansial:

- statistik bathi lan rasio pasar:

DYN - Penghasilan resik|Bathi resik sing dikarepake Dyne Therapeutics, Inc.|DYN - Rasio rega marang bathi|Rasio rega marang bathi mangsa ngarep dyne-tx.com|DYN - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Dyne Therapeutics|DYN - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajroning taun lumaku Dyne Therapeutics|DYN - Bathi resik saben saham sajrone 12 wulan pungkasan|Kacepetan wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan dyne-tx.com|DYN - Wutah bathi ing taun lumaku|Dinamika bathi saben saham sing diarepake ing taun ngarep Dyne Therapeutics, Inc.

Ringkesan analitik perusahaan:DYN, Dyne Corp

Produk sing diprodhuksi Dyne Therapeutics, Inc.

This indicator measures real cash flow from core operations, adjusted for non-cash charges and fiscal burdens, allowing for an assessment of the business's internal efficiency. An analysis of EBITDA reflects the ability of Dyne Therapeutics, Inc. (DYN) to fund the development of innovative RNA platforms for the treatment of myopathies, leveraging its high reputation within the scientific community.

Analisis pesaing Dyne Therapeutics, Inc.